Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $54.1152W HIGH $92.59
Volume
1.31 M
Value Traded
684.82 M
Short % Float
4.65%
-2.18%Week
-0.46%1 Month
+11.39%3 Month
+30.42%6 Month
-16.31%5 Year
+2,287.42%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
31.49 B
EPS (TTM)
2.65
P/E Ratio
31.52
Ent. Value
30.95 B
Total Shares
377.44 M
Float Shares
371.12 M
Insiders
1.65%
Institutions
105.01%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DXCM Catalyst Timeline
Dated clinical, regulatory and corporate events for DexCom, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for DexCom, Inc.
80Total events
2Upcoming
5Tier-1 (high impact)
2018 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Oral PresentationPresentation
Dexcom report released in advance of EASD 2026 62nd Annual Meeting
Diabetessource ↗
●PublicationPresentation
Dexcom publishes 'State of Type 2 Report: Global Access and Attitudes to Diabetes Technology'
Type 2 Diabetessource ↗
▲Partnership / LicenseCorporate
Dexcom becomes official continuous glucose monitor of Team Novo Nordisk
●Timing GuidancePresentation
Dexcom report released in advance of EASD 2026 Annual Meeting
Type 2 Diabetessource ↗
●Management ChangeCorporate
Jereme Sylvain promoted to Chief Operating Officer in addition to CFO role
▲FDA Feedback ReceivedFDA Meeting
Dexcom selected as first participant in FDA's TEMPO Digital Health Devices Pilot Program
▲Other Regulator MilestoneEx-US Regulatory
Health Canada authorization for Dexcom G7 15 Day CGM
diabetessource ↗
▲Other Regulator MilestoneEx-US Regulatory
Health Canada authorization for Dexcom G7 15 Day CGM
diabetessource ↗
▲Full ResultsClinical Data
Dexcom CONNECT Study results demonstrating CGM benefits for people with Type 2 diabetes not using insulin
Type 2 Diabetessource ↗
▲Oral PresentationPresentation
Showcased clinical evidence at ATTD 2026 including one-year registry data for Dexcom G7 in type 2 diabetes not on insulin
type 2 diabetessource ↗
▲Product LaunchPost-Market
Expanded launch of Dexcom G7 15 Day CGM across all channels in the United States
diabetessource ↗
◆Oral PresentationPresentation
Dexcom management presentation at 47th Annual Raymond James Institutional Investors Conference
▲Product LaunchSteloPost-Market
Enhanced Smart Meal Logging and Daily Insights features launch nationwide
glucose managementsource ↗
●Oral PresentationPresentation
Jake Leach presents at 44th Annual J.P. Morgan Healthcare Conference
◆Management ChangeCorporate
CEO Succession Plan Announced: Jake Leach to Become CEO Effective January 1, 2026
▲Product LaunchPost-Market
Dexcom Academy launched in Belgium, Germany, Saudi Arabia, Netherlands, Spain
diabetessource ↗
▲Product LaunchSteloPost-Market
AI-powered meal logging feature launched in Stelo app
diabetessource ↗
▲Other Regulator MilestoneEx-US Regulatory
Expanded access to Dexcom G7 for anyone on insulin as part of Ontario Drug Benefit Program in Canada
diabetessource ↗
▲First Patient DosedTrial
Received FDA clearance for Dexcom Smart Basal, first CGM-integrated basal insulin dosing optimizer
diabetessource ↗
▲Other Regulator MilestoneEx-US Regulatory
Expanded access to Dexcom CGM in Quebec under RAMQ for eligible adults with type 2 diabetes
type 2 diabetessource ↗
▲Product LaunchPost-Market
Launch of Dexcom G7 15 Day System Expected in Second Half 2025
diabetessource ↗
▲Oral PresentationPresentation
Clinical Data Presented at ADA 85th Scientific Sessions
gestational diabetes, type 2 diabetessource ↗
●Quarterly UpdateCorporate
Dexcom reports Q1 2025 financial results with revenue of $1.036 billion
▲Quarterly UpdateCorporate
Full year 2025 guidance updated: revenue $4.63-4.65B, non-GAAP gross profit margin ~61%, non-GAAP operating margin ~20-21%, adjusted EBITDA margin ~29-30%
●NDA SubmissionRegulatory Filing
Submitted Dexcom G7 15-day CGM system to the FDA for review
diabetessource ↗
▲Other Regulator MilestoneEx-US Regulatory
Secured reimbursement for Dexcom ONE+ in France for people with type 2 diabetes on basal insulin
type 2 diabetes on basal insulinsource ↗
▲Partnership / LicenseCorporate
Announced strategic partnership with URA for integration of Dexcom glucose data with Oura Ring data
Past FDA Catalysts and PDUFA Decisions
How DXCM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D28 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 74%
Mid Cap(rank 487 of 658)
Percentile Rank
DexCom, Inc. faces pipeline headwinds (28/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every DXCM program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Stern SadieOfficer (EVP Chief People & Culture Off) | Sell | -2,565 123,478 held | $86.15 | 09/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DXCM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 6.8 % (9.7 %) | 55.26 M | 820.48 K | 17.52% ( 122.32 K) |
DXCM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DXCM ranks across every disease it competes in
Competitive Position is a premium feature
See how DXCM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDXCM News
DXCM▼ -1.2%today
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
Dexcom, Inc. has announced the release date for its third quarter 2026 financial results, set for October 29, 2026. The earnings will be disclosed after market close, followed by a conference call at 4:30 p.m. Eastern Time. This call will be available via a webcast on the company's investor relations website.
Read more →DXCM▼ -1.2%today
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
Dexcom, Inc. has launched the fifth season of its Dexcom U program, featuring a record 27 college athletes with diabetes. This year's roster includes 12 newcomers and 15 returning athletes across 13 sports. The expansion is supported by research indicating a decline in stigma surrounding diabetes among young athletes.
Read more →DXCMDexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
Dexcom, Inc. has published its 'Dexcom State of Type 2 Report' ahead of the EASD 2026, focusing on global access and attitudes towards diabetes technology. The report reveals significant opportunities for improving diabetes care. Additionally, Dexcom announced a partnership with Team Novo Nordisk to serve as their official continuous glucose monitor.
Read more →DXCMDexcom Promotes Jereme Sylvain to Chief Operating Officer
Dexcom has announced the promotion of Jereme Sylvain to Chief Operating Officer. This strategic move is expected to bolster the company's operational capabilities and drive future growth. Sylvain's leadership is anticipated to play a crucial role in advancing Dexcom's objectives.
Read more →DXCMDexcom Appoints Glenn Boehnlein to Board of Directors
Dexcom, Inc. has appointed Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Boehnlein is a seasoned healthcare executive with over 20 years of experience in the medical technology sector. His previous role was as Vice President and CFO of Stryker Corporation, which enhances his qualifications for the board.
Read more →DXCMDexcom Announces Upcoming Conference Presentation
Dexcom, Inc. has announced that its management will present an update at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The presentation is set to begin at 8:00 AM EDT and will be available via a live webcast. This event aims to keep investors informed about the company's developments.
Read more →DXCM▲ +12%on this news
Dexcom Reports Second Quarter 2026 Financial Results
Dexcom, Inc. reported strong financial results for Q2 2026, with a 13% revenue increase to $1.308 billion. The company also highlighted positive findings from the CONNECT trial, which showed significant improvements in glucose control for type 2 diabetes patients. Additionally, Dexcom hosted its 2026 Investor Day, outlining its market opportunities and long-term financial outlook.
Read more →DXCMDexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Dexcom has been selected as the first participant in the FDA's TEMPO Pilot Program, which aims to assess innovative digital health technologies for chronic disease management. This initiative is designed to generate real-world evidence to support the effectiveness of these technologies. Dexcom's involvement marks a significant step in advancing digital health solutions.
Read more →DXCMDexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
Dexcom, Inc. has received authorization from Health Canada for its Dexcom G7 15 Day Continuous Glucose Monitoring System. This system is designed for adults aged 18 and older living with diabetes. It boasts the longest wear time and high accuracy, providing real-time glucose readings for up to 15.5 days.
Read more →DXCMDexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
Dexcom, Inc. has announced the release date for its second quarter 2026 financial results, which will occur after market close on July 30, 2026. Following the release, management will conduct a conference call at 4:30 p.m. Eastern Time to discuss the company's performance. The call will also be available via webcast.
Read more →DXCMDexcom Further Advances Vision of Glucose Biosensing for All
Dexcom is making strides in glucose biosensing technology, aiming to enhance accessibility for all users. The company's vision focuses on improving glucose monitoring solutions, although specific advancements or details were not provided in the article. This initiative reflects Dexcom's commitment to innovation in diabetes management.
Read more →DXCM▲ +5.2%on this news
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
The article mentions the Dexcom CONNECT Study, which highlights the benefits of continuous glucose monitoring (CGM) for individuals with Type 2 diabetes who are not using insulin. However, the content is limited and does not provide detailed findings or implications from the study.
Read more →DXCMDexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users
Dexcom has reported a theft involving a scrapped product, which may have implications for users. The company is actively notifying those who might be affected by this incident. This situation raises concerns about product security and the potential risks to user safety.
Read more →DXCM▲ +5.6%on this news· ran to +17% by day 3
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
Dexcom has announced the launch of Dexcom Flex, a continuous glucose monitoring (CGM) system aimed at individuals with type 2 diabetes in Germany. This new product is expected to enhance diabetes management for patients. Further details about the features and benefits of Dexcom Flex were not provided in the announcement.
Read more →DXCMDexcom Announces Governance Enhancements Ahead of 2026 Investor Day
Dexcom has announced governance enhancements as it prepares for its 2026 Investor Day. The details of these enhancements have not been disclosed in the article, but they indicate a proactive approach to corporate governance ahead of the event.
Read more →DXCMDexcom to Host Investor Day on May 14, 2026
Dexcom has announced that it will host an Investor Day on May 14, 2026. This event is expected to provide insights into the company's future strategies and developments. Further details about the agenda and speakers have yet to be disclosed.
Read more →DXCMDexcom Reports First Quarter 2026 Financial Results
Dexcom, Inc. reported strong financial results for the first quarter of 2026, highlighting a 15% increase in revenue year-over-year, reaching $1.192 billion. The company achieved significant growth in both U.S. (11%) and international (26%) markets, with notable improvements in gross and operating margins. Furthermore, Dexcom has raised its 2026 guidance for key financial metrics, reflecting ongoing operational improvements. The adoption of the Dexcom G7 continuous glucose monitoring system and enhanced Stelo platform features contribute positively to its growth outlook.
Read more →DXCMDexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
Dexcom has announced the schedule for its first quarter 2026 earnings release and conference call. The event is set for April 30, 2026, at 4:30 p.m. Eastern Time. This announcement provides stakeholders with a timeline for financial updates.
Read more →DXCMDexcom Announces Upcoming March 2026 Conference Presentation
Dexcom, Inc. has announced that its management will present at the 47th Annual Raymond James Institutional Investors Conference on March 2, 2026. The presentation will begin at approximately 1:05 PM EST and will be available via live webcast. This event underscores Dexcom's ongoing commitment to investor relations and transparency.
Read more →DXCMDexcom Appoints Rick Osterloh to Board of Directors
Dexcom, Inc. has announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Osterloh, a prominent technology leader at Google, brings over 20 years of experience in consumer products and innovation. His appointment is seen as a strategic move to bolster Dexcom's mission in improving metabolic health through advanced biosensing technologies. The company aims to leverage his expertise in product development and long-term strategic planning.
Read more →About DexCom, Inc.
Headquarters6340 SEQUENCE DRIVE, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next DXCM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime